Forendo Pharma Ltd

Forendo Pharma Ltd specializes in the development of innovative treatments aimed at addressing reproductive health issues, including endometriosis and infertility, through advanced therapeutic mechanisms. Founded in 2013, Forendo Pharma Ltd operates out of Turku, Finland, focusing on reproductive health therapies. The company has engaged in 6 deals, with its most recent funding round occurring in November 2021, raising EUR 5. 00 mn led by Sunstone Life Science Ventures.

Forendo was acquired by Organon BioSciences N. V. in the same month, with financial terms undisclosed. CEO Risto Lammintausta leads the firm, which has not reported any significant changes in business strategy or operations since its inception.

Forendo specializes in healthcare solutions that provide proprietary therapies targeting reproductive health conditions such as endometriosis and infertility. Their products utilize advanced therapeutic mechanisms designed to meet critical clinical needs. Forendo primarily serves healthcare providers, including hospitals and specialized clinics, and directly reaches consumers in Europe and North America, where the demand for effective reproductive health treatments remains high. Forendo Pharma's revenue model is based on business-to-business transactions, supplying therapies to hospitals and clinics that treat patients with reproductive health issues.

In the most recent year reported, the company generated zero revenue. For the year 2023, the EBITDA was reported at EUR -51,624,278. 30. Forendo Pharma plans to leverage the funds raised in November 2021 to enhance product development and expand into new markets, although specific new products or release dates have not been disclosed.

The company aims to target additional regions for expansion, focusing on enhancing its market presence in Europe and North America. The strategic acquisition by Organon BioSciences N. V. may further support these growth initiatives.